Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIGERR-HL: tislelizumab plus gemcitabine/cisplatin for relapsed or refractory Hodgkin lymphoma
NL-OMON60294Phase 2Active, not recruiting
- Sponsor
- HOVON
- Start
- Jul 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, gemcitabine and cisplatin in Hodgkin lymphoma (HL), sponsored by HOVON. Primary endpoint: Progression-free survival probability at 2 years. Started Jul 2023; status: active, not recruiting.
02
Drugs
tislelizumabgemcitabinecisplatin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NL-OMON60294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60294.